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Conclusion The association between osteoporosis and cardiovascular dis-
ease is a reality. However mechanisms are not well known.Thus it could be
interesting to suggest a DXA to coronary patients and a large cardiovascular
investigation for osteoporotic patients.
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Introduction evaluation of filling pressures and longitudinal systolic left
ventricular function in the acute coronary syndrom (ACS) isn’t common prac-
tice. Our aim is to demonstrate the prognostic of tissuedoppler mitral to ACS.
Material and Methods prospective study of 6months included all patients
admited for STEMI. Exploration of diastole was performd by studying the profile
mitral annulus and the longitudinal systolic function by DTI of left ventricular.
Results A total of 124 patients.the mean age was 61±10years old. A male
predominance of 73%. Hypertension and diabetics was the frequent cardiovas-
cular factor. Elevation of filling pressure was significantly correlated with the
risk of hospital mortality (p<0,05) ans occurence of major cardiovascular
events (p<0,005). A value of S’VG<4cm/s is predictive of the risk of death
and major cardiovacsular event (p<0,05).
Conclusion evaluation with DTI in ACS proves interesting in the risk
stratification to identify groups must benefit from intensive treatment.
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Background Because most randomised trials assessing beta-blocker therapy
after acute myocardial infarction (AMI) antedate the era of reperfusion and
modern secondary prevention, there are discrepancies among guidelines
regarding their use in this setting. We analysed data from the French registry on
ST- and non-ST-elevation Myocardial Infarction (FAST-MI) 2005, to assess the
impact of early prescription and prolonged beta-blocker therapy after AMI.
Methods FAST-MI included 3,670 consecutive patients with AMI
throughout France at the end of 2005. Detailed therapy at discharge and over
follow-up (5 years) was recorded. We studied associations 1) between beta-
blockers at discharge and one-year mortality, 2) between persistence of beta-
blocker therapy at one year and 5-year mortality. Cox multivariate analysis
and propensity score matching were used.
Results Of 2,727 patients with no history of heart failure and no left ven-
tricular dysfunction, 2,168 were prescribed beta-blockers at discharge (80%).
One-year mortality was lower in patients on beta-blockers (4.7% vs 12.2%),
adjusted hazard ratio 0.76, 0.53-1.10. Among the 1,630 patients discharged on
beta-blockers, alive at one year, and with medical prescriptions available, 184
(11%) had stopped beta-blockers. Five-year mortality was 8.8% in patients
who continued beta-blockers, versus 13.0% in those who discontinued.
Adjusted hazard ratio for 5-year death was 1.01 (0.59-1.73). Propensity score
analyses confirmed these findings.
Conclusion Our results suggest that discontinuing beta-blockers beyond one
year has no deleterious impact, but that early beta-blocker treatment may be ben-
eficial. Until further randomised trials are performed, these data can provide useful
information for future recommendations on beta-blocker use after AMI. 
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Background Current guidelines recommend a low-density lipoprotein cho-
lesterol (LDL-C) target of <1.8mmol/l for coronary patients and the adminis-
tration of high potency statin therapy. 
Purpose Our study documents real world lipid target achievement, including
distance to target, among patients with stable coronary heart disease (CHD) and
patients surviving an acute coronary syndrome (ACS) event in Europe.
Methods DYSIS II is a multicountry, observational cross-sectional chart
review conducted in 257 sites throughout Belgium, France, Germany, Greece,
Ireland, Italy, and Russia. Two distinct patient cohorts were enrolled: patients
surviving an ACS event and patients diagnosed with stable CHD. Full lipid
profiles were available within 24 hours of hospital admission for ACS patients
and 0-12 months prior to enrollment for CHD patients. Patients were on lipid-
lowering therapy (LLT) ≥3 months and not participating in clinical trials
involving medication. Patient characteristics, risk factors, treatment patterns,
and laboratory values were collected. LDL-C target achievement was assessed
based on ESC/EAS guidelines.
Results 880 ACS and 2778 CHD patients currently on LLT were enrolled
in Europe from 2012 to 2014. Only 23.2% (n=204) ACS and 29.6% (n=821)
CHD patients achieved and LDL-C<1.8mmol/l, with median distance to LDL-
C target in patients not a goal being 0.9mmol/l (IQR 0.4, 1.5) in ACS and
0.6mmol/l (IQR 0.3, 1.1) in CHD patients.
Conclusion Three out of four coronary patients did not achieve the recom-
mended LDL-C target, even while being treated with LLT, primarily statin
monotherapy.
Low potency statin treatment was found in both patient cohorts, despite the
high risk of our patient population and the need for more intense LLT (as
stressed by our distance to target findings).
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Atorvastatin equivalent dose (mg/day)
Statin monotherapy
Statin + ezetimibe
Statin + other non-statin 
(fibrates, omega 3 fatty acids)
Non-statin monotherapy
4.4±1.2
2.6±1.0
1.6±0.9
1.1±0.3
3.3±1.2
22±17
87.2%
6.4%
2.4%
3.8%
4.1±1.0
2.3±0.8
1.5±0.8
1.2±0.4
2.9±0.9
27±20
79.8%
11.6%
6.7%
2.0%
